Back to homepage

Haematology and Oncology

Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies

Authors: Sonam Puri MD, Michael Shafique MD

This review discusses the rationale, outcomes, and challenges of combination immune checkpoint blockade in non-small-cell lung cancer (NSCLC).


Activity of platinum and cetuximab in cutaneous squamous cell cancer not amenable to curative treatment

Authors: Donata Galbiati MD, Stefano Cavalieri MD, Salvatore Alfieri MD, Carlo Resteghini MD, Cristiana Bergamini MD, Ester Orlandi MD, Francesca Platini MD, Laura Locati MD, Luca Giacomelli PhD, Lisa Licitra MD, Paolo Bossi MD

This retrospective study aimed to review outcomes in patients with non-curable cutaneous squamous cell cancers treated with platinum-based chemotherapy and cetuximab.


Corrigendum: Breakthroughs in hereditary angioedema management: a systematic review of approved drugs and those under research

Authors: Stefania Nicola MD, Giovanni Rolla MD, Luisa Brussino MD

Onset of vitiligo following targeted therapy for BRAFV600E-mutated melanoma: case report

Authors: Sonia Brugnara MD, Mariacristina Sicher MD, Elena Maria Bonandini MD, Mattia Barbareschi MD, Carlo Renè Girardelli MD, Orazio Caffo MD

This case study covers a patient who received dabrafenib and trametinib and developed vitiligo-like depigmentation after treatment cessation.


Drug therapy for double-hit lymphoma

Authors: Vania Phuoc MD, Jose Sandoval-Sus MD, Julio C Chavez MD, MS

This review discusses the role of hematopoietic stem cell transplantation (HCT) and chimeric antigen receptor (CAR) T-cell therapy in DHL, as well as the role of potential novel agents such as BCL2 inhibitors, checkpoint inhibitors, bromodomain and extraterminal (BET) family inhibitors, Pi3K inhibitors, and others.